about
Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids.Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer functionVariation at 3p24.1 and 6q23.3 influences the risk of Hodgkin's lymphomaA genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells.The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma.A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.Evidence of Inbreeding in Hodgkin Lymphoma.Heritability estimates on Hodgkin's lymphoma: a genomic- versus population-based approachDendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance.Regulation of self-ligands for activating natural killer cell receptors.Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer.Role of Exosomes Released by Dendritic Cells and/or by Tumor Targets: Regulation of NK Cell PlasticityKinesin-5 Blocker Monastrol Protects Against Bortezomib-Induced Peripheral Neurotoxicity.Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia.Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies.The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.Induction of the DNA damage response by IAP inhibition triggers natural immunity via upregulation of NKG2D ligands in Hodgkin lymphoma in vitro.The Unique Molecular and Cellular Microenvironment of Ovarian CancerAntigen Loss Variants: Catching Hold of Escaping Foes.RIG-I activation induces the release of extracellular vesicles with antitumor activity.Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients.Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure.Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma.ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro.A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo.Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.The fully human anti-CD30 antibody 5F11 activates NF-{kappa}B and sensitizes lymphoma cells to bortezomib-induced apoptosis.Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines.Depletion of cellular cholesterol and lipid rafts increases shedding of CD30.Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation.NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset.Extracellular vesicles released from chronic lymphocytic leukemia cells exhibit a disease relevant mRNA signature and transfer mRNA to bystander cells.NKp30 and its ligands: emerging players in tumor immune evasion from natural killer cells.
P50
Q27329648-BEA846AF-D68C-4E25-AAD4-D0033DB9225EQ28854563-A1B0AF62-FEE3-4293-A37F-810ED5426D4DQ28943378-85BDF2A6-8E0F-4B2F-97DB-5FEC78E529EDQ28943455-E5A34A3C-A426-4759-B794-0284F3C8CC5BQ33292289-A1088571-D39E-4531-8FD4-F6CEA8B632DFQ35053177-14B35F24-D909-4246-853C-D8FFAA35CAC9Q35128470-AF7B8407-9F89-46A1-BD50-D50E8B17A036Q35925674-A75D7748-965E-47DB-9096-5CCAA16CA24FQ36001617-7F3B8B39-8D38-4CF8-9707-37B17FB8295EQ36695195-BFB6A508-C71C-4C19-BAD3-03AAC54930C1Q36821101-8E607418-960A-487B-87AF-E51DBD5443F8Q37327528-CF4F1BD8-B9E8-4555-A4DD-849408890700Q37616478-596FB581-D7FD-4861-AF65-333676963BABQ37876089-184793E1-58E1-4FE6-B2EE-7135FE56C75FQ38108820-163CA1C7-7DF1-4EF3-8968-A1093773FFB6Q38165533-D767A394-72E9-4C81-B6D4-9B64ECF6FCB5Q38196804-4E164D3C-25EC-40F4-B7B2-58E9240AF591Q38726608-7B758A57-6A47-44CF-9409-25ECA66235B1Q38739764-84D3E430-E02E-437A-9546-777BB1CB1D3BQ39000284-78A83C34-EFDB-4ECB-8D9F-6834B55CB4A7Q39037081-94E34298-7CC1-45CA-9605-6DC2425DA084Q39062237-4CF69DE8-C7BA-4DBD-8883-18D7BE0CEBDBQ39137091-FF7B726A-DA04-483C-899E-BD5A25C792CCQ39169603-A75A67A6-442E-4453-9C14-8515AD0E764AQ39175440-7603AEE2-EE3B-4FAC-B588-A1508A1D0723Q39181844-6E7B3913-093E-4B9C-BDFA-8E03750299FBQ39185522-D70623A8-C6AB-4A12-9AA0-D34A302E3C1DQ39441385-F2A78AC5-67C0-43B1-AF69-98DEB32281F2Q39551912-E1FFC447-9ABE-41A1-92D5-117FA550D550Q40185345-64FA248C-4FD2-4616-A028-37871806B015Q40364814-05C6C67F-BD08-4768-AB6A-0CA436DEBB7CQ40372471-D8071D1C-2475-4624-AAED-0CD97A7B0837Q40425646-54C1E35D-A89A-4D4F-9ECF-1C23FB1EC2BDQ40524771-BFAFC681-580B-4D6F-AA4B-6D7CEE436FCEQ40575827-258BE291-726A-476C-8668-617DC769B823Q41067927-1DB52799-D0DB-4798-857E-03EBEA2E3CB4Q41472587-99ED11EA-A91C-4D48-BA6F-349C7650254DQ41699529-901199F7-E02A-4304-BAC8-98DB56826BABQ42361976-9BC7BA87-F908-4DBE-881C-F2F171D4B38FQ43143910-101C69A3-3F6A-47B5-91C1-3AF454F1A0DB
P50
name
Elke Pogge von Strandmann
@ast
Elke Pogge von Strandmann
@de
Elke Pogge von Strandmann
@en
Elke Pogge von Strandmann
@es
Elke Pogge von Strandmann
@fr
Elke Pogge von Strandmann
@nl
type
label
Elke Pogge von Strandmann
@ast
Elke Pogge von Strandmann
@de
Elke Pogge von Strandmann
@en
Elke Pogge von Strandmann
@es
Elke Pogge von Strandmann
@fr
Elke Pogge von Strandmann
@nl
prefLabel
Elke Pogge von Strandmann
@ast
Elke Pogge von Strandmann
@de
Elke Pogge von Strandmann
@en
Elke Pogge von Strandmann
@es
Elke Pogge von Strandmann
@fr
Elke Pogge von Strandmann
@nl
P214
P227
P21
P213
0000 0004 0123 1417
P214
P227
1067910883
P31
P735
P7859
viaf-314881103